Trial Profile
A Real-world study to evaluate the safety and efficacy of Apatinib in patients with Advanced Neuroendocrine Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology